CAR-T comes to Europe: Novartis and Gilead receive EU approvals
In a landmark decision, the European Commission has approved both Novartis’ Kymriah and Gilead’s Yescarta for the treatment of patients within the EU.
In a landmark decision, the European Commission has approved both Novartis’ Kymriah and Gilead’s Yescarta for the treatment of patients within the EU.
China has accredited ABEC to make and supply bioprocessing equipment from its Kells facility in Ireland.
Preparations for an “unlikely” ‘no deal’ Brexit are underway in the UK, with the government instructing pharmaceutical companies to build their medicine reserves before March 2019.